Stocks › IOVA
Iovance Biotherapeutics IOVA
US equityMarket cap rank #2386
$6.90 −$0.41 (-5.61%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $6.99 +1.25%
Open$7.17
Prev close$7.31
Day range$6.77 – $7.40
Volume13.73M
Market cap$3.19B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$121.47M+80.1% YoY
Operating profit-$23.97M+73.3% YoY
Net profit-$22.27M+75.6% YoY
Diluted EPS-$0.05+80.0% YoY
Free cash flow-$9.31M+89.6% YoY
Operating cash flow-$4.47M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin53.2%
Operating margin-60.8%
Net margin-58.2%
Return on equity-29.1%
Return on assets-23.3%
Return on invested capital-28.4%
Current ratio5.20
Liabilities / assets18.0%
Cash & investments$376.32M
Total debt$42.77M
Net cash (debt)$333.55M
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $121.47M | $99.31M | $71.43M | $263.50M | $86.77M |
| Total Operating Revenue | $121.47M | $99.31M | $71.43M | $263.50M | $86.77M |
| Cost of Revenue | $48.03M | $43.60M | $42.50M | $173.18M | $43.11M |
| Gross Profit | $73.44M | $55.72M | $28.93M | $90.32M | $43.66M |
| Operating Expense | $97.41M | $107.62M | $109.98M | $488.53M | $117.12M |
| Selling and Admin Expenses | $38.58M | $39.27M | $38.95M | $152.32M | $36.40M |
| Research & Development | $49.34M | $58.85M | $62.49M | $300.27M | $71.20M |
| Depreciation & Amortization & Depletion | $9.50M | $9.50M | $8.54M | $35.94M | $9.52M |
| -Depreciation & Amortization | $9.50M | $9.50M | $8.54M | $35.94M | $9.52M |
| Operating Profit | -$23.97M | -$51.91M | -$81.04M | -$398.21M | -$73.46M |
| Net Non-Operating Interest Income (Expense) | $2.31M | $3.22M | $1.33M | $10.31M | $1.74M |
| Non-Operating Interest Income | $2.31M | $3.22M | $1.33M | $10.31M | $1.74M |
| Special Income (Charges) | $0.00 | – | – | -$5.14M | $0.00 |
| -Less:Restructuring and Mergern & Acquisition | $0.00 | – | – | $5.14M | $0.00 |
| Pretax Profit | -$21.66M | -$48.69M | -$79.71M | -$393.05M | -$71.72M |
| Tax | $614,000.00 | -$1.37M | -$665,000.00 | -$2.07M | $184,000.00 |
| Net Profit | -$22.27M | -$47.32M | -$79.05M | -$390.98M | -$71.90M |
| Profit from Continuing Operations | -$22.27M | -$47.32M | -$79.05M | -$390.98M | -$71.90M |
| Net Income to Parent Company | -$22.27M | -$47.32M | -$79.05M | -$390.98M | -$71.90M |
| Net Income to Common Stockholders | -$22.27M | -$47.32M | -$79.05M | -$390.98M | -$71.90M |
| Basic EPS | -$0.05 | -$0.11 | -$0.19 | -$1.09 | -$0.18 |
| Diluted EPS | -$0.05 | -$0.11 | -$0.19 | -$1.09 | -$0.18 |
| Other Income (Expense) | – | – | – | -$5.14M | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $991.21M | $915.53M | $925.67M | $913.17M | $913.17M |
| Total Current Assets | $549.64M | $464.26M | $466.50M | $442.69M | $442.69M |
| Cash and Cash Equivalents & Short-Term Investments | $376.32M | $110.77M | $313.44M | $296.98M | $296.98M |
| -Cash and Cash Equivalents | $57.93M | $110.77M | $196.51M | $163.08M | $163.08M |
| -Short Term Investments | $318.39M | – | $116.94M | $133.90M | $133.90M |
| Receivables | $106.99M | – | $81.76M | $82.45M | $82.45M |
| -Accounts Receivable | $106.99M | $102.12M | $81.76M | $82.45M | $82.45M |
| Inventory | $55.22M | $55.59M | $58.38M | $51.68M | $51.68M |
| Other Current Assets | $11.11M | $408.67M | $12.93M | $11.58M | $11.58M |
| Total Non-Current Assets | $441.58M | $451.27M | $459.16M | $470.48M | $470.48M |
| Net PPE | $171.87M | – | $175.78M | $177.01M | $177.01M |
| -Gross PPE | $231.99M | – | $228.15M | $225.78M | $225.78M |
| -Accumulated Depreciation | -$60.12M | – | -$52.37M | -$48.77M | -$48.77M |
| Goodwill and Other Intangible Assets | $259.21M | $263.89M | $269.10M | $279.32M | $279.32M |
| -Other Intangible Assets | $259.21M | $263.89M | $269.10M | – | – |
| Other Non-Current Assets | $10.50M | $187.38M | $14.28M | $14.15M | $14.15M |
| Total Liabilities | $178.55M | $179.49M | $203.91M | $214.59M | $214.59M |
| Total Current Liabilities | $105.77M | $106.85M | $129.42M | $138.36M | $138.36M |
| Payables | $21.65M | – | $37.45M | $22.16M | $22.16M |
| -Accounts Payable | $21.65M | $26.21M | $37.45M | $22.16M | $22.16M |
| Current Accrued Expenses | $81.69M | $77.96M | $88.07M | $111.16M | $111.16M |
| Short-Term Debt and Capital Lease Obligation | $2.44M | – | $3.90M | $5.04M | $5.04M |
| -Current Capital Lease Obligation | $2.44M | $2.67M | $2.90M | $4.04M | $4.04M |
| Total Non-Current Liabilities | $72.78M | $72.64M | $74.49M | $76.23M | $76.23M |
| Long Term Debt and Capital Lease Obligation | $42.77M | $43.33M | $43.88M | $44.40M | $44.40M |
| -Long Term Capital Lease Obligation | $42.77M | $43.33M | $43.88M | $44.40M | $44.40M |
| Non-Current Deferred Liabilities | $30.01M | – | $30.61M | $31.83M | $31.83M |
| Total Equity | $812.66M | $736.05M | $721.75M | $698.58M | $698.58M |
| Stockholders' Equity | $812.66M | $722.95M | $721.75M | $698.58M | $698.58M |
| Capital Stock | $21,000.00 | $2,000.00 | $20,000.00 | $19,000.00 | $19,000.00 |
| -Common Stock | $19,000.00 | – | $18,000.00 | $17,000.00 | $17,000.00 |
| -Preferred Stock | $2,000.00 | $2,000.00 | $2,000.00 | $2,000.00 | $2,000.00 |
| Additional Paid-In Capital | $3.72B | $3.62B | $3.56B | $3.46B | $3.46B |
| Retained Earnings | -$2.92B | -$2.90B | -$2.85B | -$2.78B | -$2.78B |
| Gains/Losses Not Affecting Retained Earnings | $13.85M | – | $12.65M | $16.44M | $16.44M |
| -Current Debt | – | – | $1.00M | $1.00M | $1.00M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$4.47M | -$60.84M | -$72.07M | -$302.41M | -$52.57M |
| Net cash flow from continuing operations | -$4.47M | -$60.84M | -$72.07M | -$302.41M | -$52.57M |
| Net Income from Continuing Operations | -$22.27M | -$47.32M | -$79.05M | -$390.98M | -$71.90M |
| Gain/Loss from Continuing Operations | $62,000.00 | -$355,000.00 | $462,000.00 | -$194,000.00 | -$373,000.00 |
| Depreciation & Depletion & Amortization | $10.42M | $10.40M | $10.42M | $47.32M | $12.64M |
| Deferred Tax | $614,000.00 | -$1.37M | -$665,000.00 | -$2.07M | $184,000.00 |
| Change in Working Capital | -$3.34M | -$35.83M | -$12.88M | -$24.27M | -$7.29M |
| -Change in Receivables | -$4.87M | -$20.36M | $690,000.00 | -$13.11M | -$15.69M |
| -Change in Inventory | $596,000.00 | -$177,000.00 | -$4.93M | -$14.21M | -$4.00M |
| -Change in Prepaid Assets | -$282,000.00 | $5.91M | -$1.47M | -$8.02M | -$661,000.00 |
| -Change in Payables and Accrued Expense | $2.01M | -$20.43M | -$5.15M | $21.98M | $15.96M |
| -Change in Other Current Liabilities | -$792,000.00 | -$773,000.00 | -$2.03M | -$10.90M | -$2.90M |
| Net cash flow from investing | -$134.65M | -$74.05M | $11.39M | $47.50M | $775,000.00 |
| Net Cash Flow from Continuing Investing Activities | -$134.65M | -$74.05M | $11.39M | $47.50M | $775,000.00 |
| Net PPE Purchase and Sale | -$4.74M | -$5.44M | -$6.61M | -$33.84M | -$9.32M |
| Net Investment Purchase and Sale | -$129.81M | -$68.61M | $18.00M | $81.33M | $10.10M |
| Financing Cash Flow | $86.28M | $49.29M | $94.34M | $300.77M | $56.17M |
| Net Cash Flow from Continuing Financing Activities | $86.28M | $49.29M | $94.34M | $300.77M | $56.17M |
| Net Common Stock Issuance | $87.90M | $49.57M | $98.51M | $306.31M | $55.78M |
| Proceeds from Stock Option Exercised | $805,000.00 | $887,000.00 | $0.00 | $1.53M | $839,000.00 |
| Net Other Financing Charges | -$2.42M | -$1.17M | -$4.18M | -$7.06M | -$445,000.00 |
| Ending Cash Balance | $63.95M | $116.77M | $202.50M | $169.06M | $169.06M |
| Net Change in Cash | -$52.83M | -$85.60M | $33.66M | $45.86M | $4.38M |
| Beginning Cash Balance | $116.77M | $202.50M | $169.06M | $122.05M | $164.10M |
| Effect of Exchange Rate Changes | $11,000.00 | -$124,000.00 | -$213,000.00 | $1.14M | $577,000.00 |
| Free Cash Flow | -$9.31M | -$66.28M | -$78.68M | -$336.24M | -$61.89M |
| Net Business Purchase and Sale | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on IOVA.
Sign in to join the discussion.